Nothing Special   »   [go: up one dir, main page]

WO2008090959A1 - エフェクター活性が増強された遺伝子組換え抗体組成物 - Google Patents

エフェクター活性が増強された遺伝子組換え抗体組成物 Download PDF

Info

Publication number
WO2008090959A1
WO2008090959A1 PCT/JP2008/050993 JP2008050993W WO2008090959A1 WO 2008090959 A1 WO2008090959 A1 WO 2008090959A1 JP 2008050993 W JP2008050993 W JP 2008050993W WO 2008090959 A1 WO2008090959 A1 WO 2008090959A1
Authority
WO
WIPO (PCT)
Prior art keywords
genetically recombinant
recombinant antibody
antibody composition
antibody
effector activity
Prior art date
Application number
PCT/JP2008/050993
Other languages
English (en)
French (fr)
Inventor
Kenya Shitara
Rinpei Niwa
Akito Natsume
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to ES08703820.4T priority Critical patent/ES2538990T3/es
Priority to AU2008208288A priority patent/AU2008208288B2/en
Priority to EP08703820.4A priority patent/EP2119780B1/en
Priority to CA2676529A priority patent/CA2676529C/en
Priority to JP2008555104A priority patent/JP5071942B2/ja
Priority to KR1020097017511A priority patent/KR101578940B1/ko
Priority to CN200880008735.1A priority patent/CN101679966B/zh
Publication of WO2008090959A1 publication Critical patent/WO2008090959A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

　本発明は、ヒトIgG1抗体であって、KabatらのEUインデックスで示される276番目および339番目のアミノ酸が置換されたCH2ドメインを有し、かつアミノ酸置換する前のCH2ドメインを有する抗体よりも補体依存性細胞傷害活性が増加した、遺伝子組換え抗体組成物、該遺伝子組換え抗体組成物に含まれる抗体分子または該抗体分子の重鎖定常領域をコードするDNA、該DNAを宿主細胞に導入して得られる形質転換体、該形質転換体を用いた遺伝子組換え抗体組成物の生産方法、ならびに該遺伝子組換え抗体組成物を有効成分として含有する医薬に関する。
PCT/JP2008/050993 2007-01-24 2008-01-24 エフェクター活性が増強された遺伝子組換え抗体組成物 WO2008090959A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES08703820.4T ES2538990T3 (es) 2007-01-24 2008-01-24 Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
AU2008208288A AU2008208288B2 (en) 2007-01-24 2008-01-24 Genetically recombinant antibody composition having enhanced effector activity
EP08703820.4A EP2119780B1 (en) 2007-01-24 2008-01-24 Genetically recombinant antibody composition having enhanced effector activity
CA2676529A CA2676529C (en) 2007-01-24 2008-01-24 Genetically recombinant antibody composition having enhanced effector activity
JP2008555104A JP5071942B2 (ja) 2007-01-24 2008-01-24 エフェクター活性が増強された遺伝子組換え抗体組成物
KR1020097017511A KR101578940B1 (ko) 2007-01-24 2008-01-24 이펙터 활성이 증강된 유전자 재조합 항체 조성물
CN200880008735.1A CN101679966B (zh) 2007-01-24 2008-01-24 具有增强的效应子活性的遗传重组抗体组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007013640 2007-01-24
JP2007-013640 2007-01-24

Publications (1)

Publication Number Publication Date
WO2008090959A1 true WO2008090959A1 (ja) 2008-07-31

Family

ID=39644533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050993 WO2008090959A1 (ja) 2007-01-24 2008-01-24 エフェクター活性が増強された遺伝子組換え抗体組成物

Country Status (9)

Country Link
US (2) US7994290B2 (ja)
EP (1) EP2119780B1 (ja)
JP (1) JP5071942B2 (ja)
KR (1) KR101578940B1 (ja)
CN (1) CN101679966B (ja)
AU (1) AU2008208288B2 (ja)
CA (1) CA2676529C (ja)
ES (1) ES2538990T3 (ja)
WO (1) WO2008090959A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
CN102933604A (zh) * 2010-02-23 2013-02-13 赛诺菲 抗-α2整联蛋白抗体及其用途
US9234039B2 (en) 2010-08-31 2016-01-12 Sanofi Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same
JP2016537975A (ja) * 2013-11-12 2016-12-08 オージーディー２ ファーマ プロアポトーシス活性を有するヒトｉｇｇ１由来抗体
WO2020067541A1 (ja) * 2018-09-28 2020-04-02 協和キリン株式会社 抗体組成物
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
WO2013047729A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 標的抗原に対する免疫応答を誘導する抗原結合分子
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2014210209A2 (en) * 2013-06-27 2014-12-31 Abbvie Biotherapeutics Inc. Fc variants with improved complement activation
PL3708583T3 (pl) 2013-08-01 2022-06-06 Five Prime Therapeutics, Inc. Afukozylowane przeciwciała anty-fgfr2iiib
WO2015117229A1 (en) * 2014-02-07 2015-08-13 Mcmaster University Trifunctional t cell-antigen coupler and methods and uses thereof
EP3223865A4 (en) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CA2978185A1 (en) 2015-03-23 2016-09-29 Stephen Sazinsky Antibodies to icos
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
US11447553B2 (en) 2015-11-23 2022-09-20 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
RS62589B1 (sr) 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antitela na pd-1 i njihova upotreba
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
CA3078637A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
KR20200103706A (ko) 2017-12-22 2020-09-02 조운스 테라퓨틱스, 인크. Lilrb2에 대한 항체
CN112236446A (zh) 2018-03-29 2021-01-15 弗埃塞股份有限公司 Lfa3变体及其组合物与用途
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
MX2021002690A (es) 2018-09-07 2021-05-12 Pfizer Anticuerpos anti-avb8 y composiciones y usos de los mismos.
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
US20220135682A1 (en) 2019-03-11 2022-05-05 Jounce Therapeutics, Inc. Anti-ICOS Antibodies for the Treatment of Cancer
US20220378909A1 (en) 2019-11-05 2022-12-01 Jounce Therapeutics, Inc. Methods of Treating Cancer with Anti-PD-1 Antibodies
CA3168704A1 (en) 2020-01-24 2021-07-29 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021216417A1 (en) 2020-04-20 2021-10-28 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
US20230295274A1 (en) 2020-07-27 2023-09-21 Single Cell Technology, Inc. Anti-sars coronavirus-2 spike protein antibodies
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4347660A1 (en) 2021-06-01 2024-04-10 Triumvira Immunologics USA, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2023228082A1 (en) 2022-05-26 2023-11-30 Pfizer Inc. Anti-tnfr2 antibodies and methods of use thereof
US20240083991A1 (en) 2022-05-31 2024-03-14 Pfizer Inc. Anti-bmp9 antibodies and methods of use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
US20240052047A1 (en) 2022-08-03 2024-02-15 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
US20240165227A1 (en) 2022-11-04 2024-05-23 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
US20240226313A1 (en) 2022-11-17 2024-07-11 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024218650A1 (en) 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59140885A (ja) 1983-01-13 1984-08-13 マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ 植物細胞ゲノムへの発現可能な遺伝子の導入法
JPS6070080A (ja) 1983-02-24 1985-04-20 レイクスニベルシテイト　ライデン 双子葉植物の染色体への外来性ｄνａの組込方法
JPS60251887A (ja) 1984-05-11 1985-12-12 ノバルティス　アクチエンゲゼルシャフト 植物のプロトプラストの形質転換法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JPS63309192A (ja) 1987-02-17 1988-12-16 ファーミング　ビーブイ 効率的な分泌のための乳腺に出される蛋白におけるｄｎａ配列
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
WO1994023021A1 (en) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
JP2517813B2 (ja) 1990-05-29 1996-07-24 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 生きている細胞に生物学的物質を導入するための改良された方法および装置
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
JP2606856B2 (ja) 1986-12-05 1997-05-07 アグラシータス 生細胞中に遺伝物質担持担体粒子を注入するための装置
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
WO2003055993A1 (fr) 2001-12-25 2003-07-10 Kyowa Hakko Kogyo Co., Ltd. Composition d'un anticorps qui se lie spécifiquement à cd20
US20030158389A1 (en) 1998-04-02 2003-08-21 Genentech, Inc. Polypeptide variants
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20050054832A1 (en) 2002-03-01 2005-03-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2006088494A2 (en) * 2004-07-12 2006-08-24 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using the same
WO2006100739A1 (ja) 2005-03-18 2006-09-28 Fujitsu Limited 文書管理プログラムおよび文書管理方法
WO2007011041A1 (ja) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP3502133A1 (en) * 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
ES2349777T3 (es) * 2003-01-22 2011-01-11 Glycart Biotechnology Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora.
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59140885A (ja) 1983-01-13 1984-08-13 マツクス・プランク・ゲゼルシヤフト・ツア・フエルデルング・デア・ヴイツセンシヤフテン・エ−・フアウ 植物細胞ゲノムへの発現可能な遺伝子の導入法
JPS6070080A (ja) 1983-02-24 1985-04-20 レイクスニベルシテイト　ライデン 双子葉植物の染色体への外来性ｄνａの組込方法
JPS60251887A (ja) 1984-05-11 1985-12-12 ノバルティス　アクチエンゲゼルシャフト 植物のプロトプラストの形質転換法
JPS63299A (ja) 1986-04-22 1988-01-05 イミユネツクス・コ−ポレ−シヨン ヒトｇ−ｃｓｆタンパク質の発現
JP2606856B2 (ja) 1986-12-05 1997-05-07 アグラシータス 生細胞中に遺伝物質担持担体粒子を注入するための装置
JPS63309192A (ja) 1987-02-17 1988-12-16 ファーミング　ビーブイ 効率的な分泌のための乳腺に出される蛋白におけるｄｎａ配列
JPH02227075A (ja) 1988-09-29 1990-09-10 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP2517813B2 (ja) 1990-05-29 1996-07-24 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 生きている細胞に生物学的物質を導入するための改良された方法および装置
JPH05336963A (ja) 1991-12-17 1993-12-21 Kyowa Hakko Kogyo Co Ltd 新規α２→３シアリルトランスフェラーゼ
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
WO1994023021A1 (en) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
US20030158389A1 (en) 1998-04-02 2003-08-21 Genentech, Inc. Polypeptide variants
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
WO2003055993A1 (fr) 2001-12-25 2003-07-10 Kyowa Hakko Kogyo Co., Ltd. Composition d'un anticorps qui se lie spécifiquement à cd20
US20050054832A1 (en) 2002-03-01 2005-03-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2006088494A2 (en) * 2004-07-12 2006-08-24 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using the same
WO2006100739A1 (ja) 2005-03-18 2006-09-28 Fujitsu Limited 文書管理プログラムおよび文書管理方法
WO2007011041A1 (ja) * 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物

Non-Patent Citations (257)

* Cited by examiner, † Cited by third party
Title
"A Laboratory Manual", 1994, COLD SPRING HARBOR LABORATORY PRESS, article "Manipulating the Mouse Embryo"
"A Laboratory Manual"; Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS, article "Manipulating the Mouse Embryo"
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY
"Antibody Engineering, A Practical Approach", 1996, IRL PRESS AT OXFORD UNIVERSITY PRESS
"Biochemical Experimentation Methods 23 - Method for Studying Glycoprotein Sugar Chain", 1989, JAPAN SCIENTIFIC SOCIETIES PRESS
"Biomanual Series 8, Gene Targeting, Preparation of Mutant Mice Using ES Cells", 1995
"Biomanual Series 8, Gene Targeting, Preparation ofmutant Mice Using ES Cells", 1995
"Cell Technology, Extra Edition, Experimental Protocol Series, Glycobiology Experimental Protocol, Glycoprotein, Glycolipid and Proteoglycan", 1996, SHUJUNSHA
"Current Protocols in Molecular Biology", 1987, article "Molecular Cloning"
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS
"Current Protocols in Molecular Biology", article "Molecular Cloning"
"Current Protocols in Molecular Biology", pages: 1 - 34
"Current Protocols in Molecular Biology, Manipulating the Mouse Embryo"
"Current Protocols in Molecular Biology; A Laboratory Manual", 1989, article "Molecular Cloning"
"Current Protocols in Molecular Biology; Antibodies, A Laboratory manual", 1988, COLD SPRING HARBOR LABORATORY, article "Molecular Cloning"
"Current Protocols in Molecular Biology; Baculovirus Expression Vectors, A Laboratory Manual", 1992, W.H. FREEMAN AND COMPANY
"Current Protocols in Molecular Biology; Baculovirus Expression Vectors, A Lahoratory Manual", 1992, W. H. FREEMAN AND COMPANY
"Developmental Engineering Experimentation Manual - Preparation of Transgenic Mice", 1987
"DNA Cloning 1: Core Techniques, A Practical Approach", 1995, OXFORD UNIVERSITY
"Enzyme Antibody Technique", 1985, GAKUSAI KIKAKU
"Enzyme Immunoassay", 1987, IGAKU SHOIN
"Expression and Analysis", 1994, article "Biomanual Series 4 - Methods of Gene Transfer"
"Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS
"Molecular Cloning"
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LAB. PRESS
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"Monoclonal Antibodies: Principles and Applications", 1995, WILEY-LISS, INC.
"Monoclonal Antibodies: principles and practice", 1993, ACAD. PRESS
"Monoclonal Antibodies: Principles and Practice", 1996, ACADEMIC PRESS LIMITED
"PCR Protocols", 1990, ACADEMIC PRESS
"Saccharides 1, Glycoprotein", 1988, TOKYO KAGAKU DOJIN, article "Shin Seikagaku Jikken Koza"
"Sequence of Proteins of Immunological Interest", 1991
"Sequences of Proteins of Immunological Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES
"Sequences of Proteins oflmmunological Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES
"Sequences ofProteins o/1mmuno/ogical Interest", 1991, US DEPT. HEALTH AND HUMAN SERVICES
"Soshiki Baiyo no Gijutsu", 1996, THE JAPANESE TISSUE CULTURE ASSOCIATION
"Totanpakushitsu Tosa Kenkyuho", 1989, GAKKAI SHUPPAN CENTER, article "Seibutsukagaku Jikkenho"
AGRIC. BIOL, CHEM., vol. 55, no. 1, 1991, pages 283 - 284
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, 1996, pages 627S
AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 63, 1996, pages 639S
ANAL. BIOCHEM., vol. 171, 1988, pages 73
ANALYTICAL BIOCHEMISTRY, vol. 162, 1987, pages 156
ANN. ALLERGY ASTHMA IMMUNOL., vol. 81, 1998, pages 105
BENTLEY K. J. ET AL., HYBRIDOMA, vol. 17, 1998, pages 559 - 567
BID/TECHNOLOGY, vol. 2, 1991, pages 266
BIO/TECHNOLOGY, vol. 17, 1999, pages 1097
BIO/TECHNOLOGY, vol. 2, 1991, pages 830
BIO/TECHNOLOGY, vol. 6, 1988, pages 47
BIO/TECHNOLOGY, vol. 9, 1991, pages 266
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960
BIOCHEMISTRY, vol. 15, 1976, pages 5175
BIOCHEMISTRY, vol. 20, 1981, pages 2361
BIOSCIENCE AND INDUSTRY, vol. 50, 1992, pages 322
BIOTECHNOL. BIOENG., vol. 74, 2001, pages 288
BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614
BIOTECHNOLOGY, vol. 2, 1992, pages 358
BLOOD, vol. 99, 2002, pages 754
BRADY G. ET AL., GENE, vol. 27, 1984, pages 223 - 232
BREKKE O.H. ET AL.: "Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis", MOLECULAR IMMUNOLOGY, vol. 30, no. 16, 1993, pages 1419 - 1425, XP023935453 *
BRITISH J CANCER, vol. 83, 2000, pages 493
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 260
CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 373
CANCER IMMUNOL. IMMUNOTHER., vol. 37, 1993, pages 255
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 36, 1993, pages 373
CANCER RES., vol. 54, 1994, pages 1511
CANCER RES., vol. 57, 1997, pages 4593
CANCER RES., vol. 58, 1998, pages 3905
CANCER RES., vol. 64, 2004, pages 2127
CANCER RESEARCH, vol. 54, 1994, pages 1511
CANCER, vol. 88, 2000, pages 2909
CANFIELD S.M. ET AL.: "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, no. 6, 1991, pages 1483 - 1491, XP001181027 *
CDNA CLONING, 1996
CELL TECHNOLOGY, vol. 11, 1994, pages 255
CELL TECHNOLOGY, vol. 12, 1993, pages 239
CELL TECHNOLOGY, vol. 16, 1997, pages 1463
CELL, vol. 33, 1983, pages 717
CELL, vol. 41, 1985, pages 479
CELL, vol. 95, 1998, pages 1017
CHEMICAL IMMUNOLOGY, vol. 65, 1997, pages 88
CHEMISTRY, vol. 46, 1991, pages 681
CIRCULATION, vol. 101, 2000, pages 1158
CLIN. CANCER RES., vol. 10, 2004, pages 6248
CLIN. CANCER. RES., vol. 10, 2004, pages 6248
CURR. OPIN. ONCOL., vol. 10, 1998, pages 548
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, pages 1 - 34
CYTOKINE, vol. 3, 1991, pages 562
CYTOTECHNOLOGY, vol. 1, 1990, pages 133
CYTOTECHNOLOGY, vol. 2, 1990, pages 133
CYTOTECHNOLOGY, vol. 3, 1990, pages 133
CYTOTECHNOLOGY, vol. 3, 1990, pages 133 3
CYTOTECHNOLOGY, vol. 4, 1990, pages 173
DNA CLONING, A PRACTICAL APPROACH, vol. 1, 1985, pages 49
DNA CLONING: A PRACTICAL APPROACH, vol. I, 1985, pages 49
EUR. J. IMMUNOL., vol. 21, 1991, pages 2379
EUR. J. IMMUNOL., vol. 24, 1994, pages 2542
EUR. J. IMMUNOL., vol. 29, 1999, pages 2819
EXPERIMENTAL MEDICINE, vol. 11, 1993, pages 2491
EXPERIMENTAL MEDICINE, vol. 9, 1991, pages 1937
FEBS LETT., vol. 328, 1993, pages 49
GENE THERAPY, vol. 5, 1999, pages 1960
GENE, vol. 200, 1997, pages 149
GENE, vol. 27, 1984, pages 223
GENE, vol. 33, 1985, pages 103
GENE, vol. 34, 1985, pages 315
GENE, vol. 38, 1985, pages 275
GENES DEVELOP., vol. 4, 1990, pages 1288
GENETICS, vol. 39, 1954, pages 440
GILLIES S. D. ET AL., CELL, vol. 33, 1983, pages 717 - 728
HEPATOLOGY, vol. 25, 1997, pages 1462
HUM ANTIB HYBRID, vol. 6, 1995, pages 82
HUM. MOL GENET., vol. 5, 1995, pages 1083
HUMAN ANTIB HYBRID, vol. 5, 1994, pages 143
HYBRIDOMA, vol. 13, 1994, pages 183
IMMUNOL. REV., vol. 127, 1992, pages 5
IMMUNOL. TODAY, vol. 21, 2000, pages 364
IMMUNOL. TODAY, vol. 21, 2000, pages 403
IMMUNOLOGY, vol. 86, 1995, pages 319
INVEST. DERMATOL., vol. 111, 1998, pages 1172
J BACTERIOLOGY, vol. 153, 1983, pages 163
J BIOCHEM., vol. 101, 1987, pages 1307
J BIOL. CHEM., vol. 265, 1990, pages 16455
J BIOL. CHEM., vol. 277, 2002, pages 26733
J CLIN. DNCOL., vol. 17, 1999, pages 268
J CLIN. MICROBIOL., vol. 37, 1999, pages 396
J EXP. MED., vol. 186, 1997, pages 1373
J IMMUNOL. METHODS, vol. 167, 1994, pages 271
J IMMUNOL., vol. 152, 1994, pages 2968
J IMMUNOL., vol. 166, 2001, pages 2571
J LIQ. CHROMATOGR., vol. 6, 1983, pages 1577
J MOL. BIOL., vol. 112, 1977, pages 535
J MOL. BIOL., vol. 16, 1966, pages 118
J MOL. BIOL., vol. 166, 1983, pages 1
J MOL. BIOL., vol. 215, 1990, pages 403
J NEUROSCI. RES., vol. 40, 1995, pages 647
J. BIOCHEM., vol. 95, 1984, pages 197
J. BIOCHEMISTRY, vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 272, 1997, pages 17400
J. BIOL. CHEM., vol. 278, 2003, pages 3466
J. CLIN. ONCOL, vol. 16, 1998, pages 2825
J. CLIN. ONCOL., vol. 12, 1999, pages 2639
J. CLIN. ONCOL., vol. 21, 2003, pages 1466
J. IMMUNOL. METH., vol. 217, 1998, pages 41
J. IMMUNOL., vol. 164, 2000, pages 4178
J. IMMUNOL., vol. 172, 2004, pages 3280
J. MOL. BIOL., vol. 16, 1966, pages 118
J. MOL. MED., vol. 75, 1997, pages 829
J. NEUROSCI. RES., vol. 40, 1995, pages 647
J. RHEUMATOLOGY, vol. L5, 1998, pages 2065
J. UROLOGY, vol. 160, 1998, pages 2396
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 166, 1987, pages 1351
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, 1991, pages 1025
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, 1991, pages 1483
KABAT ET AL.: "Sequence ofProteins of Immunological Interest", 1991
KUWANA Y. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 149, 1987, pages 960 - 968
LOWE ET AL., PROC. NATL. ACAD SCI. USA, vol. 86, 1989, pages 8227
MASON J. O. ET AL., CELL, vol. 41, 1985, pages 479 - 487
METHODS ENZYMOL., vol. 194, 1990, pages 182
METHODS FOR PREPARING GENE LIBRARIES, 1994
METHODS IN ENZYMOL., vol. 154, 1987, pages 3
METHODS IN ENZYMOLOGY, vol. 154, 1987, pages 3
METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63
MIYAJI H. ET AL., CYTOTECHNOLOGY, vol. 3, 1990, pages 133 - 140
MIYAJI H. ET AL., CYTOTECHNOLOGY, vol. 4, 1990, pages 173 - 180
MIZUKAMI T.; ITOH S., J BIOCHEM., vol. 101, 1987, pages 1307 - 1310
MIZUKAMI T.; ITOH S., J. BIOCHEM., vol. 101, 1987, pages 1307 - 1310
MOL. CELL. BIOL., vol. 3, 1983, pages 280
MOL. IMMUNOL., vol. 30, 1993, pages 1419
MOL. IMMUNOL., vol. 34, 1997, pages 1019
MOL. IMMUNOL., vol. 37, 2000, pages 995
MOL. LMMUNOL., vol. 37, 2000, pages 1035
MOLECULAR IMMUNOL., vol. 31, 1994, pages 371
MOLECULAR IMMUNOL., vol. 36, 1999, pages 387
MOLECULAR PHARMACOL., vol. 58, 2000, pages 237
MORGAN A. ET AL.: "The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding", IMMUNOLOGY, vol. 86, no. 2, 1995, pages 319 - 324, XP001106372 *
NAT. BIOTECHNOL., vol. 17, 1999, pages 176
NATURE BIOTECH., vol. 16, 1998, pages 1343
NATURE BIOTECH., vol. 18, 2000, pages 43
NATURE BIOTECH., vol. 18, 2000, pages 555
NATURE BIOTECHNOL., vol. 16, 1998, pages 1015
NATURE CELL BIOL., vol. 2, 2000, pages 70
NATURE GENET., vol. 24, 2000, pages 314
NATURE GENET., vol. 25, 2000, pages 35
NATURE MEDICINE, vol. 4, 1998, pages 285
NATURE REVIEWS CANCER, vol. 1, 2001, pages 119
NATURE, vol. 195, 1962, pages 788
NATURE, vol. 227, 1970, pages 680
NATURE, vol. 312, 1984, pages 643
NATURE, vol. 321, 1986, pages 522
NATURE, vol. 329, 1987, pages 840
NATURE, vol. 332, 1988, pages 323
NATURE, vol. 391, 1998, pages 806
NATURE, vol. 395, 1998, pages 854
NATURE, vol. 400, 1999, pages 776
NUC. ACIDS RES., vol. 27, 1999, pages 1323
NUCLEIC ACID AND ENZYME, vol. 41, 1996, pages 603
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487
NUCLEIC ACIDS RESEARCH, vol. 11, 1985, pages 4431
NUCLEIC ACIDS RESEARCH, vol. 17, 1989, pages 9494
O'HARE K. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 78, 1981, pages 1527 - 1531
ONCOGENE, vol. 19, 2000, pages 2138
ONCOGENE, vol. 22, 2003, pages 7359
PAULSON ET AL., J BIOL. CHERN., vol. 264, 1989, pages 17619
PERI ET AL., J IMMUNO. METH., vol. 174, 1994, pages 249 - 257
PROC, NAIL ACAD. SCI. USA, vol. 96, 1999, pages 5049
PROC, NATL. ACAD SCI. USA, vol. 95, 1998, pages 15502
PROC. NATL. ACAD SCI. U.S.A., vol. 89, 1992, pages 4285
PROC. NATL. ACAD SCI. US.A., vol. 78, 1981, pages 1527
PROC. NATL. ACAD SCI. USA, vol. 84, 1978, pages 1929
PROC. NATL. ACAD SCI. USA, vol. 84, 1987, pages 7413
PROC. NATL. ACAD SCI. USA, vol. 89, 1992, pages 4285
PROC. NATL. ACAD SCI. USA, vol. 96, 1999, pages 1451
PROC. NATL. ACAD SCI. USA, vol. 96, 1999, pages 8774
PROC. NATL. ACAD. SCI USA, vol. 82, 1985, pages 488
PROC. NATL. ACAD. SCI. US.A., vol. 96, 1999, pages 1886
PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 1929
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851
PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 9911
PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285
PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13959
PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 8768
PROC. NATL. ACAD. SCI., USA, vol. 79, 1982, pages 6409
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1
PROTEIN ENGINEERING, vol. 7, 1994, pages 1501
SANGER ET AL., PROC, NATL. ACAD SCI. U S.A, vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD SCI. USA, vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD SCI., USA, vol. 74, 1977, pages 5463
SANGER ET AL., PROC. NATL. ACAD. SCI. USA., vol. 74, 1977, pages 5463
SATO M. ET AL.: "Kotai no Tosa Kozo to Effector Kassei", MOLECULAR MEDICINE, vol. 40, no. 9, 2003, pages 1024 - 1032 *
SCAND. J IMMUNOL., vol. 32, 1990, pages 517
SCAND. J. IMMUNOL., vol. 15, 1982, pages 275
SCIENCE, vol. 122, 1952, pages 501
SCIENCE, vol. 222, 1983, pages 778
SCIENCE, vol. 253, 1991, pages 1129
SCIENCE, vol. 273, 1996, pages 1386
See also references of EP2119780A4
SHITARA K. ET AL., J. LMMUNOL. METHODS, vol. 167, 1994, pages 271 - 278
SOMATIC CELL MOL. GENET., vol. 12, 1986, pages 51
SOMATIC CELL MOL. GENET., vol. 12, 1986, pages 555
SOSHIKI BAIYO, vol. 20, 1994
SOSHIKI BAIYO, vol. 21, 1995
STRATEGIES, vol. 5, 1992, pages 58
STRATEGIES, vol. 5, 1992, pages 81
STRUCTURE, vol. 8, 2000, pages 2
STRUCTURE, vol. 8, 2000, pages 385
SUGANO ET AL., GENE, vol. 138, 1994, pages 171
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
THOMMESEN J.E. ET AL.: "Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation", MOLECULAR IMMUNOLOGY, vol. 37, no. 16, 2000, pages 995 - 1004, XP002522213 *
TMMUNOL. TODAY, vol. 20, 1999, pages 576
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 132
TRENDS IN BIOTECHNOLOGY, vol. 10, 1992, pages 87
TRENDS IN BIOTECHNOLOGY, vol. 12, 1997, pages 45
TRENDS IN BIOTECHNOLOGY, vol. I0, 1992, pages 152
VAN LOGHEM E. ET AL.: "Staphyloccocal protein A and human IgG subclasses and allotypes", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 15, no. 3, 1982, pages 275 - 278, XP008112596 *
VIROLOGY, vol. 8, 1959, pages 396
YAMANE-OHNUKI N. ET AL.: "Establishment for FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOLOGY AND BIOENGINEERING, vol. 87, no. 5, 1993, pages 614 - 622, XP002984450 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933604A (zh) * 2010-02-23 2013-02-13 赛诺菲 抗-α2整联蛋白抗体及其用途
US8975376B2 (en) 2010-02-23 2015-03-10 Sanofi Anti-alpha2 integrin antibodies and their uses
CN102933604B (zh) * 2010-02-23 2016-04-06 赛诺菲 抗-α2整联蛋白抗体及其用途
US11267891B2 (en) 2010-02-23 2022-03-08 Sanofi Fc variant antibodies and their uses
WO2011118739A1 (ja) 2010-03-26 2011-09-29 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
US9234039B2 (en) 2010-08-31 2016-01-12 Sanofi Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same
JP2016537975A (ja) * 2013-11-12 2016-12-08 オージーディー２ ファーマ プロアポトーシス活性を有するヒトｉｇｇ１由来抗体
US11466093B2 (en) 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
WO2020067541A1 (ja) * 2018-09-28 2020-04-02 協和キリン株式会社 抗体組成物
JPWO2020067541A1 (ja) * 2018-09-28 2021-08-30 協和キリン株式会社 抗体組成物
US20210380684A1 (en) * 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Antibody composition
JP7529568B2 (ja) 2018-09-28 2024-08-06 協和キリン株式会社 抗体組成物

Also Published As

Publication number Publication date
KR101578940B1 (ko) 2015-12-18
CA2676529C (en) 2014-03-25
CA2676529A1 (en) 2008-07-31
CN101679966A (zh) 2010-03-24
US20120022238A1 (en) 2012-01-26
EP2119780A1 (en) 2009-11-18
EP2119780A4 (en) 2010-08-25
CN101679966B (zh) 2014-03-12
US20090004186A1 (en) 2009-01-01
US7994290B2 (en) 2011-08-09
JPWO2008090959A1 (ja) 2010-05-20
AU2008208288B2 (en) 2014-04-03
EP2119780B1 (en) 2015-03-25
US8492526B2 (en) 2013-07-23
AU2008208288A1 (en) 2008-07-31
ES2538990T3 (es) 2015-06-25
JP5071942B2 (ja) 2012-11-14
KR20090112723A (ko) 2009-10-28

Similar Documents

Publication Publication Date Title
WO2008090959A1 (ja) エフェクター活性が増強された遺伝子組換え抗体組成物
EP1921090A4 (en) GENETICALLY MODIFIED ANTIBODY COMPOSITION
WO2008090960A1 (ja) ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
WO2008090958A1 (ja) ドメイン交換された遺伝子組換え抗体組成物
RU2495050C2 (ru) Связующий элемент для рецептора gm-csf
EP2581113A4 (en) ANTI-TIM-3 ANTIBODIES
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
WO2009001840A1 (ja) ADCC活性又はCDC活性を有する抗Prominin-1抗体
WO2010083434A3 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
BRPI0717363B8 (pt) imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina
RU2012129735A (ru) Антитела к her3 и их применения
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
WO2011038933A3 (en) Anti-hsv antibody
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
UA117294C2 (uk) Імунокон'югат
JP2016512425A5 (ja)
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
EP2543727A4 (en) MODIFIED ANTIBODY COMPOSITION
NO20055209L (no) Peptabody for cancerbehandling
CN107847600A (zh) 抗CD20抗体与Bcl‑2抑制剂和MDM2抑制剂的组合疗法
WO2010115995A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
KR20230078657A (ko) 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880008735.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703820

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008555104

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2676529

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008208288

Country of ref document: AU

Ref document number: 4376/CHENP/2009

Country of ref document: IN

Ref document number: 2008703820

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008208288

Country of ref document: AU

Date of ref document: 20080124

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097017511

Country of ref document: KR